Wednesday, October 14, 2026

Coffee Futures Went Down By Over 2% In The Last 5 Sessions

ViaNews Editorial Team

December 29, 2023

Coffee Futures Went Down By Over 2% In The Last 5 Sessions

(VIANEWS) - Coffee (KC) has been up by 2.8% for the last 5 sessions. At 10:51 EST on Friday, 29 December, Coffee (KC) is $187.80.

Volume

Today's last reported volume for Coffee is 10321, 49.26% below its average volume of 20342.84.

Volatility

Coffee's last week, last month's, and last quarter's current intraday variation average was a positive 1.27%, a negative 2.89%, and a positive 2.65%, respectively.

Coffee's highest amplitude of average volatility was 1.27% (last week), 3.55% (last month), and 2.65% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Coffee's commodity is considered to be oversold (<=20).

News about

  • According to FXStreet on Thursday, 28 December, " Oil traders will keep an eye on the EIA Crude Oil Stocks Change report, due on Thursday. "
  • Crude oil eases despite red sea tensions, WTI slips back towards $74.00. According to FXStreet on Wednesday, 27 December, "US Crude Oil stocks continue to flaunt expectations of declining reserves, and both the American Petroleum Institute (API) and the Energy Information Administration (EIA) will be publishing updated barrel buildup figures on Wednesday and Thursday, respectively.", "The API Weekly Crude Oil Stocks count last posted a 939K barrel increase last week while the EIA Crude Oil Stocks Change last showed a buildup of nearly three million barrels, and is forecast to print a -2.6 million barrels reduction for the week ended December 22."

More news about Coffee (KC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com